NCT01732406已完成不适用
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 126
- 试验地点
- 1
- 主要终点
- Acromegaly Quality of Life (ACROQoL) Global Score
研究概览
简要总结
The investigators hypothesize that treatment of acromegaly will be associated with an improvement in quality of life compared to active acromegaly. At the same time, they will also be studying the effects of different acromegaly treatments on the quality of life.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-90
- •Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin analog monotherapy
排除标准
- •Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be stable for at least 3 months prior to entry into the study
- •Initiation or discontinuation of testosterone or estrogen within 3 months of entry
- •Pregnant and nursing women
结局指标
主要结局
Acromegaly Quality of Life (ACROQoL) Global Score
时间窗: Cross-sectional at baseline
The Global Score of the Acromegaly Quality of Life (ACROQoL) Survey measures quality of life in patients with acromegaly. Higher scores indicate better QOL. The range is 22-110 units on a scale.
次要结局
- The Gastrointestinal Quality of Life Index (GIQLI) Total Score(Cross-sectional at baseline)
- 36-Item Short Form Survey Instrument (SF-36) Physical Health(Cross-sectional at baseline)
- 36-Item Short Form Survey (SF-36) Mental Health Summary Score(Cross-sectional at baseline)
研究者
Karen Klahr Miller, MD
Assistant Physician in Medicine
Massachusetts General Hospital
研究点 (1)
Loading locations...
相似试验
撤回
不适用
Growth Hormone Use in Adolescents and Adults With Cystic FibrosisCystic FibrosisNCT00287430University of Texas Southwestern Medical Center
招募中
不适用
Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional StudyAcromegalyNCT05964712Istituto Auxologico Italiano30
Unknown
2 期
Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian ResponseInfertility, FemaleNCT03373149Riyadh Fertility and Reproductive Health center228
进行中（未招募）
不适用
Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GHSpinal muscular atrophy (SMA) is an autosomal recessive disease. Due to the genetic defect, a molecule called spinal motor neuron” (SMN) protein is lacking, resulting in muscle weakness. In SMAs muscle weakness is found most often at the level of proximal muscles. The disease is life-threatening and chronically debilitating.EUCTR2005-002822-78-DEKlinik Neuropädiatrie und Muskelkrankheiten20
已完成
4 期
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionAcromegalyNCT00145405Odense University Hospital12